Abstract
The receptor for the lipid mediator PAF (PAFR) is a G-protein coupled receptor expressed in several cell types. Besides PAF, a series of oxidized phospholipids can also bind to PAFR. Dying cells also express PAFR-ligands and, in both situations, scavenger receptors are involved as well. There is evidence that the scavenger receptor CD36 and PAFR associate in the macrophages membrane and signal in conjunction to induce a regulatory phenotype. In the tumor microenvironment, apoptotic cells are abundant due to hypoxia, and PAF-like phospholipids are generated. Engagement of PAFR expressed by tumor macrophages and dendritic cells induces a regulatory/tolerogenic phenotype and subverts the innate and adaptive immune response to the tumor. During cancer therapies, PAFR-ligands can be generated, further aggravating the immune suppression. Moreover, some tumor cells express PAFR and its activation by PAFR-ligands generated during chemotherapy induce anti-apoptotic factors, which protect the tumor cells from death induced by these treatments. It is proposed that PAFR antagonists, administered in combination with chemotherapy, may represent a promising strategy for cancer treatment.
Keywords: Chemotherapy, PAF receptor, tumor growth, tumor macrophages, tumor microenvironment.
Current Drug Targets
Title:PAF Receptor and Tumor Growth
Volume: 15 Issue: 10
Author(s): Sonia Jancar and Roger Chammas
Affiliation:
Keywords: Chemotherapy, PAF receptor, tumor growth, tumor macrophages, tumor microenvironment.
Abstract: The receptor for the lipid mediator PAF (PAFR) is a G-protein coupled receptor expressed in several cell types. Besides PAF, a series of oxidized phospholipids can also bind to PAFR. Dying cells also express PAFR-ligands and, in both situations, scavenger receptors are involved as well. There is evidence that the scavenger receptor CD36 and PAFR associate in the macrophages membrane and signal in conjunction to induce a regulatory phenotype. In the tumor microenvironment, apoptotic cells are abundant due to hypoxia, and PAF-like phospholipids are generated. Engagement of PAFR expressed by tumor macrophages and dendritic cells induces a regulatory/tolerogenic phenotype and subverts the innate and adaptive immune response to the tumor. During cancer therapies, PAFR-ligands can be generated, further aggravating the immune suppression. Moreover, some tumor cells express PAFR and its activation by PAFR-ligands generated during chemotherapy induce anti-apoptotic factors, which protect the tumor cells from death induced by these treatments. It is proposed that PAFR antagonists, administered in combination with chemotherapy, may represent a promising strategy for cancer treatment.
Export Options
About this article
Cite this article as:
Jancar Sonia and Chammas Roger, PAF Receptor and Tumor Growth, Current Drug Targets 2014; 15 (10) . https://dx.doi.org/10.2174/1389450115666140903111812
DOI https://dx.doi.org/10.2174/1389450115666140903111812 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets New Peptidic GnRH Antagonists Offer a Broad Range of Therapeutic Applications
Letters in Drug Design & Discovery Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Current Drug Targets <i>In vivo</i> Evaluation of [<sup>225</sup>Ac]Ac-DOTA<sup>ZOL</sup> for α-Therapy of Bone Metastases
Current Radiopharmaceuticals Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Muscarinic Acetylcholine Receptors: New Potential Therapeutic Targets in Antinociception and in Cancer Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Novel Non-rodent Models of Kidney Disease
Current Molecular Medicine Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Gold Nanomaterials: From Preparation to Pharmaceutical Design and Application
Current Pharmaceutical Design Thymoquinone, an Active Compound of Nigella sativa: Role in Prevention and Treatment of Cancer
Current Pharmaceutical Biotechnology Anti-Cancer Activity of Nitrones and Observations on Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Ganglioside GD3 as a Raft Component in Cell Death Regulation
Anti-Cancer Agents in Medicinal Chemistry MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews